Oliver Bechter

23PUBLICATIONS
234CO-AUTHORS
Molecular targetsPredictive and prognostic markersTumour immunologyGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|May 13, 2026
Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.

|Mar 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With <i>BRAF</i> V600-Mutant Solid Tumors.

Maria Vieito, Elisa Fontana, Catherine H Han

|Nov 07, 2025
The assembly of cancer-specific ribosomes by the lncRNA LISRR suppresses melanoma anti-tumor immunity.

Sonia Cinque, Yvessa Verheyden, Sara Adnane

|Jun 18, 2025
Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype.

Joanna Pozniak, Niccolò Roda, Ewout Landeloos

|Mar 28, 2025
A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors.

Oliver Bechter, Carmen Loquai, Stephane Champiat

|Mar 17, 2025
Activated T Cells Break Tumor Immunosuppression by Macrophage Reeducation.

Rosa Trotta, Silvia Rivis, Shikang Zhao

Pageof 4

Frequent Collaborators

9 joint publications

Francesca Maria Bosisio

7 joint publications

Jean-Christophe Marine

5 joint publications

Diether Lambrechts

4 joint publications

Ewout Landeloos